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ABSTRACT
Introduction: The yellow fever epidemic that occurred in 1972/73 in Central Brazil surprised the majority of the population 
unprotected. A clinical-epidemiological survey conducted at that time in the rural area of 19 municipalities found that the highest 
(13.8%) number of disease cases were present in the municipality of Luziânia, State of Goiás. Methods: Thirty-eight years 
later, a new seroepidemiological survey was conducted with the aim of assessing the degree of immune protection of the rural 
population of Luziânia, following the continuous attempts of public health services to obtain vaccination coverage in the region. A 
total of 383 volunteers, aged between 5 and 89 years and with predominant rural labor activities (75.5%), were interviewed. The 
presence of antibodies against the yellow fever was also investigated in these individuals, by using plaque reduction neutralization 
test, and correlated to information regarding residency, occupation, epidemiological data and immunity against the yellow fever 
virus. Results: We found a high (97.6%) frequency of protective titers (>1:10) of neutralizing antibodies against the yellow 
fever virus; the frequency of titers of 1:640 or higher was 23.2%, indicating wide immune protection against the disease in the 
study population. The presence of protective immunity was correlated to increasing age. Conclusions: This study reinforces the 
importance of surveys to address the immune state of a population at risk for yellow fever infection and to the surveillance of 
actions to control the disease in endemic areas.
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Despite the ever-changing locations of occurrences of the 
disease in the country, for a long time the Central-West region 
of Brazil is part of the yellow fever’s endemic and enzootic area. 
In Goiás, a State in the Central-West region, cases of wild-type 
yellow fever disease have been detected since 19351, and in 
the 70´s this was the State of Brazil with the highest incidence 
of this disease2.
During the epidemic in 1972/73, the Núcleo de Medicina 
Tropical da Universidade de Brasília conducted a clinical-
epidemiological survey in the rural area of 19 municipalities 
around the Federal District. The study area corresponded to 
76,558km2 and a population of 471,133 inhabitants. At that 
time, we investigated 812 individuals with family members in 
which the disease was suspected or confirmed and identified 
295 (36.3%) cases of the disease, most of them 130 (44.1%) 
cases, classified as mild disease (fever without jaundice, 
bleeding or renal failure). Sixty-nine (23.4%) cases were 
classified as moderate disease (jaundice with constitutive 
symptoms) and 96 (32.5%) cases, as severe disease (with 
classical clinical presentation). Among the latter cases, the 
overall mortality was 94.8%3. Only 22 (7.5%) of all patients 
reported previous immunization against yellow fever. Most 
(68.1%) patients were young adults, aged 29 years or less, and 
male (66.1%). In addition, most cases were seen in December 
1972. Although it is possible that some individuals may have 
acquired protective immunity due to previous asymptomatic or 
oligosymptomatic natural infection, it was noticed that a large 
part of the population exposed to the risk of infection had no 
immune defense against the arbovirosis (unpublished data).
The rural communities in Luziânia had the highest number of 
yellow fever cases during the epidemic in 1972/734. Since then, 
the disease has been considered of great sanitary importance to 
the region and these communities have been included in several 
vaccination campaigns. It is possible that due to these preventive 
actions the number of confirmed cases of yellow fever in Goiás 
has diminished significantly from 1990 to 2000, to a total of 
88 cases, with 45 deaths5.
In addition to its importance to the previous epidemic of 
yellow fever, the municipality of Luziânia constitutes an endemic 
yellow fever area, with a current rural population of 11,000, and 
is therefore an important target for immunization actions plans 
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and epidemiological surveillance. For these reasons, we sought 
to investigate the degree of immune protection of this population 
38 years later, by means of a serologic survey.
The aim of this survey was to investigate the impact of the 
intensification of immunization actions on the protection against 
yellow fever since the occurrence of the 1972/72 epidemics, due 
to the importance of periodic field surveys to acknowledge the 
immune state of the population exposed to the disease and to 
monitor control actions in endemic areas.
Study area
Luziânia is the fifth most populated municipality in the 
State of Goiás and is located approximately 200km from 
Goiânia, the state capital, and 60km from Brasília (Figure 1). 
It is part of the Região Integrada de Desenvolvimento (RIDE) 
of the Federal District. It has 174,531 inhabitants, of whom 
162,807 live in the urban areas, whereas 11,724, in rural areas6. 
Luziânia is crossed by the rivers Corumbá, São Bartolomeu, 
Descoberto, Piracanjuba, and Areias, which form the basin of the 
Paraná River. The dominant vegetation is typical of the cerrado, 
with riparian forests that can be found along riverbanks along 
with different species of primates, mainly from Callitrichidae 
and Cebidae7 families. The wild vectors are mainly of the 
Haemagogus and Aedes genera8.
Clinical-serological survey
The survey was conducted from August 19 to October 9, 
2010 in 24 rural areas or farms affected by the epidemic in 72/73. 
All its inhabitants who agreed to participate in the study were 











FIGURE 1 - Map of Brazil, highlighted the State of Goiás and the municipality of 
Luziânia.
answered a previously developed questionnaire containing 
information about age, sex, address, occupation, lifestyle, travels, 
residency proximity to native vegetation and plantation, presence 
of primitive primates and marsupials near residency, current 
symptoms, general health conditions (including the occurrence of 
fever and jaundice with or without bleeding, from 1972 to 2010), in 
addition to their vaccination history. A brief physical examination 
foccused on the investigation of signs of anemia, jaundice, bleeding, 
hepato and splenomegaly. Blood samples were collected and 
maintained at room temperature for 2-6h. The serum obtained was 
frozen at -20°C until it was sent, using containers with dry ice, to 
the cell culture laboratory of the Arbovirology and Hemorrhagic 
Fevers Department of the Evandro Chagas Institute to detect 
antibodies against the yellow fever virus. For this, plaque reduction 
neutralization test (PRNT) was adapted and used, according 
to the protocol described by Stefano et al.9. The samples were 
tested in serial dilutions (range, 1:05-1:640) and compared to an 
average of 20 plaque-forming units of yellow fever virus. 
Seropositivity was considered when the titer was above or equal 
to 1:10, whereas when the titer was below 1:10, seronegativity 
was considered10,11.
Vaccination was indicated in all the volunteers included in 
the study whose results showed low immune response against 
the disease.
Individuals who showed their vaccination card with the 
registration stamp of yellow fever vaccination and/or reported 
prior vaccination were considered as vaccinated. However, 
immunization status was considered only for those who had 
neutralizing antibodies titers above 1:10.
Statistical analysis
The sample size was estimated at 372 individuals, calculated 
as proposed by Lwanga and Lemeshow12, considering a 
confidence level of 95%, and an error margin of ±5% (or 0.05), 
in a 11,724 population (estimated rural population of Luziânia6). 
As we could not estimate the anticipated population proportion, 
the value of 0.5 was established.
For association tests, chi-square and Fischer tests were used, 
whereas for means comparisons, Student´s t test and analysis of 
variance (ANOVA), followed by Turkey test were used. To assess 
the correlation between variables of normal distribution the Pearson´s 
correlation coefficient was used. For all he tests mentioned above, 
the results were considered statistically significant when p<0.05. 
Ethical considerations
The research project was approved by the Ethics Committee 
on Human Research of the Faculty of Medicine of the 
University of Brasília, under the registration data CEP-FM/UnB 
n: 041/2010.
Clinical-epidemiological survey
We interviewed 383 volunteers who were residents in the 
rural area of Luziânia. The average residency time in the region 
was 19.58 years (range, 0-81 years; median, 12 years). The age 
of the individuals participating in the study varied between 5 and 
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TABLE 1 - Analysis of the association of demographic, epidemiological, and clinical variables, with yellow fever immune statusa
 OR (95%CI) p
Gender 1.0194 (0.2695-3.8562) 0.9774
Age 1.054 (1.009-1.099) 0.016
Time of residency 1.0358 (0.9836-1.0907) 0.1828
Occupation (inside rural area/outside rural area)b,c -- --
Primates in peridomestic habitats 1.38 (0.29-6.68) 0.46
Vegetation in peridomestic habitats 0.7574 (0.0918-6.2459) 0.7963
Type of vegetation (cerrado/riparian forest) in peridomestic habitats 0.44 (0.02-3.59) 0.38
Plantation in peridomestic habitats 0.9726 (0.1186-7.9773) 0.9794
Vaccination against YF 0.3294 (0.0385-2.8180) 0.3106
Prior YFb,d  -- --
Prior jaundiceb,e -- --
Post vaccination time 0.9894 (0.7303-1.3405) 0.9451
YF: yellow fever; OR: odds ratio; CI: confidence interval; atiters > 10, positive or immune; and ≤ 10, negative or non-immune; bimpaired analysis due to the absence of a 
comparison group; cno volunteer with occupation outside the rural area presented titration of neutralizing antibodies against YF≤10; d all volunteers with a history of previous YF 
presented titration of neutralizing antibodies against yellow fever > 10; e only one volunteer with prior jaundice history showed titration of neutralizing antibodies against YF>10.
89 years old (average age, 39.2 years), of which 211 (55.1%) 
were women and 172 (44.9%), men.
The majority of the people included in the survey were 
natives, 243 (63.4%), whereas 140 (36.6%) were from other 
regions, mainly from the northeastern states (47.1%). The main 
activities (75.5%) were conducted in the rural area, being mostly 
farmers, housewives, health officials, caretakers, and students. 
The presence of woodland near residency was reported by 
348 (90.4%) of the subjects, and in 284 (82.1%) cases the 
distance from woodland to residency was smaller than 500m. 
Vegetable and fruit-gardens near residency were reported by 337 
(88%) individuals, whereas the frequency of primitive primates 
near residency was 222 (58%).
Twenty (5.2%) residents did not recall whether they had 
underwent prior yellow fever vaccination, whereas 15 (3.9%) 
stated that they had not received any vaccination. Out of 
348 (90.9%) individuals who received prior vaccination, 
70 (20.1%) could not remember the number of doses that they 
received. Among the 278 (79.9%) individuals who informed the 
number of doses that they received, an average of 2.7 individuals 
received doses varying between 1 and 10. Further, 94.6% of these 
individuals received up to 5 doses of the vaccine (Figure 2). 
Additionally, 19 (5.5%) claimed that they were vaccinated more 
than 10 years ago; 244 (70.1%), less than 10 years ago; and 85 
(24.4%), did not recall the date of the last vaccination. 
Among the interviewees, 3 (0.8%) individuals had prior 
occurrence of yellow fever: one manifested the disease 2 years 
before the study, whereas the others, 38 and about 50 years 
before, respectively. They were all residing in the State of Goiás 
while presenting the disease. All 3 stated that, once recovered, 
they were vaccinated against yellow fever.
During the study, none of the participants presented 


























Number of doses of vaccine against YF
FIGURE 2 - Distribution of the individuals interviewed and vaccinated against yellow 
fever in the rural area of the municipality of Luziânia, in 2010, according to the number 
of doses of vaccine already received. YF: yellow fever.
Serological survey
The 383 participants in the study underwent serological analysis 
by using the PRNT. A total of 374 (97.6%) volunteers presented 
positive values (titers above 1:10); 7 (1.8%), negative (below 1:10); 
and 2 (0.5%) borderline titer values (1:10). Among the individuals 
with titer values above 1:10, the average titration was 1:329, after 
considered the majority of those examined (89 [23.2%]) had a titer 
≥ 1:640. Thus, it was not possible to establish a correlation between 
the post-vaccination time and the yellow fever antibody titer.
In the assessment of variables referring to personal data 
with the immunity against yellow fever, a correlation was found 
(p = 0.016) only between the ages of the participants in the 
survey (Table 1 and Figure 3). 
Nine (2.3%) people interviewed showed no immune protection, 
including 5 women and 4 men; of these, 6 were aged under 
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FIGURE 3 - Distribution of neutralizing antibodies titers in 383 individuals examined 
in rural Luziânia in 2010, according to age. YFV: yellow fever vaccines.
Among the adults, one stated that he was a rural worker and 
the other 2 did household chores. The time of residence in 
their current location varied between a few months to up to 
41 years. Four individuals denied the presence of non-human 
primates around their homes, whereas 5 confirmed it. With 
the exception of one individual, 8 among those interviewed were 
vaccinated against yellow fever (1, 7 years ago; and 7, 2 years ago). 
Among the 6 individuals who claimed to have received prior 
vaccination, one individual received 3 doses; two, 2 doses; and 
three, one dose.
DISCUSSION
Although the current annual number of cases of yellow 
fever in Brazil reported rarely exceed 40 notifications5, the 
last revision of the occurrence area of the disease in Brazil has 
indicated the expansion of yellow fever, between 2007 and 2009, 
to the reaching unvaccinated population in the States São Paulo, 
Paraná and Rio Grande do Sul. However the State of Goiás is still 
responsible for a significant number of yellow fever cases. In the 
70s, Goiás was the Federal State that registered a high number 
of yellow fever cases2 in the country, as its rural population was 
shown to be the most susceptible to this pathology8.
During the epidemic in the summer of 1972/73, which 
occurred in Central Brazil, the Núcleo de Medicina Tropical 
da Universidade de Brasília (NMT-UnB) promoted a clinical-
epidemiological survey in the rural area of 19 affected 
municipalities, 18 belonging to the State of Goiás. Thirty-eight 
years later, the rural communities in the municipality of Luziânia 
were revisited. This municipality is located in the middle of the 
endemic area in which the highest number of disease cases was 
registered during the epidemic. A serological re-evaluation was 
conducted with the aim of verifying the real degree of current 
immune protection of the population that has been continuously 
exposed to the risk of infection.
The result of the survey conducted in 1972/73 by the 
NMT/UnB showed a higher frequency of disease cases (295) 
and deaths (91) than those officially registered, namely, 71 and 
44 cases, respectively8. In fact, many cases occurring in wild 
regions are left unreported, suggesting a yellow fever iceberg 
hypothesis13. Yellow fever has a wide spectrum of possible clinical 
presentations, from asymptomatic to severe cases, and therefore 
its clinical diagnosis may be challenging in situations other that 
epidemics, particularly in the absence of bleeding and renal 
dysfunction14. Even during outbreaks, it may be misdiagnosed 
as other diseases that present with jaundice and bleeding, such 
as leptospirosis, which may be occur concomitantly in regions 
affected by yellow fever. In reality, the frequency of disease 
cases must be even higher than what was revealed by the study 
promoted by the NMT/UnB, which aimed at families in which 
at least one confirmed episode of yellow fever was detected. 
A correlation between the absence of vaccination prior to disease 
and severe forms of the pathology was confirmed. The result 
of the serological tests with 56.4% negative titers in 55 serum 
samples obtained from unvaccinated individuals show that a large 
part of the population was without immune protection against 
arbovirosis, thus, being susceptible to infection (unpublished data).
Since the implementation of the yellow fever vaccine in 1998, 
as part of the Expanded Program of Immunization15, the vaccination 
coverage in the State of Goiás has achieved much higher rates 
than that of previous immunizations. In 2010, the official 
vaccination coverage (based on applied doses) in the municipality 
of Luziânia reached 100.8%16. Considering this improvement, 
it is safe to assume a similar increase in immunological 
protection of the studied population in 2010 than that in 1972/73.
In the survey conducted in 2010, the majority of the 
population interviewed were young individuals, aged between 
20 and 59 years old, working at or near the place of residence and 
living mainly in a rural setting. Most of the people interviewed 
were residing in that region for more than 10 years, showing 
stability in the place of residence, in addition to the proximity 
to woodlands and to primitive primates, which are important 
factors in the sylvatic cycle of yellow fever transmission17. 
Thus, no significant change from the time of the epidemic in 
1972/73 was observed in age, migratory as well as occupational 
characteristics of the population living in the study area.
Although the vaccination coverage foreseen by the National 
Program of Immunization is 100% for municipalities located in 
the risk zone, 3.9% of the individuals interviewed reported no 
prior vaccination. Although 90.9% received prior vaccination 
against yellow fever, we can infer a higher frequency of 
vaccinated individuals than that reported. This is possible by 
assuming a recall bias, that those unaware of receiving prior 
vaccination were vaccinated either at some point in their lives 
but did not remember or became infected and developed mild 
or oligosymptomatic forms of the disease. Thus, although 
the information suggests that the vaccination coverage was 
below that recommended by the Ministry of Health, it might 
still be considered a high vaccination coverage18. However, 
the serological survey showed that 97.7% of the individuals 
presented protective levels of neutralizing antibodies. This 
enabled us to conclude that in that region, the vaccination 
coverage against yellow fever was effective, because evident 
progress was observed than that after the epidemic of 1972/73, 
which affected most of the unprotected population.
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Eight individuals reported previous vaccination, in some of 
them confirmed by information in the immunisation card, but did 
not show protective titers of antibodies. Some hypothesis were 
drawn to explainthis finding: a) the possibility of confusion with 
vaccination against other disease, which could have been offered to 
the inhabitants of the studied area in the same period as yellow fever 
vaccination; b) the interference of other vaccines, administered 
simultaneously, in the immune response; c) inadequate storing 
conditions of the vaccine, preceding its administration; 
d) impairment of the immune response in some individuals. 
Unfortunately, our results preclude the exact definition of the 
mechanisms underlying the absence of protective antibodies in 
individuals who reported previous vaccination.
The data that 94.6% of the individuals received up to 
5 doses of the vaccine reflects the increase in vaccination 
coverage over the past years, since the inclusion of the vaccine 
in immunization programs for children and adults by the World 
Health Organization (WHO) and the Pan American Health 
Organization and its implementation in the Expanded Program 
on Immunization in 199816.
To evaluate the protective immune response against yellow 
fever, PRNT was used as the gold standard, since it showed 
higher sensitivity and specificity to assess protective immunity 
than other serological tests19,20. Plaque reduction neutralization 
test measures antibodies against neutralizing epitopes and 
determines antibody functionality, a parameter correlated 
with high specificity for protective immunity21. Neutralizing 
antibodies against yellow fever virus are different from those 
against other flaviviruses21, a feature that renders this test highly 
specific. Although it cannot differentiate antibodies induced by 
natural infection from those induced by active immunization, 
this does not invalidate the current study, which was designed 
to investigate the immune state of the population against the 
disease. There is no consensus on the titration conferring 
immunity. However, the values used as positive, i.e., values 
more than 10 are well accepted in the literature10,11,19,21,22.
While assessing a possible association with variables 
referring to personal data, only a correlation between the 
older individuals interviewed and high titer of the neutralizing 
antibodies was established. Probably, this was due to multiple 
exposures and/or vaccinations. No indicative data were 
confirmed, because no consensus was found in the literature 
regarding the higher titers shown by Caucasians than by Blacks 
and Hispanics, as well as by men than by women20,22-24. In a 
Brazilian study, a lower seroconversion rate was observed 
on antibody levels after vaccination against yellow fever in 
12-month-old children who simultaneously received the triple 
viral vaccine than in those who received the 30-day interval 
vaccination. In the same study, an increased probability of 
presenting primary failure was shown in children with median 
age of 9 months, who developed no humoral response to the 
first dose of vaccination than in children with a median age of 
12 months. This effect was observed despite most of the children 
presenting humoral response after the second vaccine dose, 
although they showed no response to primary vaccination25. 
Presumably, the majority of the children, who were residents in 
the rural areas of Luziânia, were simultaneously immunized with 
other vaccines because of their obvious difficulty in accessing 
health services. Most of the rural community was vaccinated 
during vaccination campaigns. This might be an explanation 
for the correlation established between the children interviewed 
and their low titers of neutralizing antibodies.
Among the 15 individuals who had never been vaccinated 
against yellow fever before, only one did not show neutralizing 
antibodies. Presumably, those with immunization had a recall 
bias or had prior vaccination in some point in their lives, 
particularly during childhood, or may have developed protective 
antibodies due to an asymptomatic or oligosymptomatic form of 
the disease. It is unlikely that individuals showing neutralizing 
antibodies against yellow fever virus, although denying prior 
vaccination, developed these antibodies because of cross-
immunity with other arboviruses. Further, to supporting this 
observation, the PRNT detects antibodies against neutralizing 
epitopes that are specific to the yellow fever virus.
Despite the official numbers for vaccination coverage, no 
immunological protection was observed in 9 (2.3%) people 
interviewed, among whom 3 were adults. With the exception of 
one individual who denied prior vaccination, 8 stated that they 
received vaccination against yellow fever at some point in their 
lives. As a seroconversion rate of above 90% is expected in adults 
immunized with a 17DD vaccine strain21,26. The vulnerability in 
the serologic response of this group, which includes 3 adults, 
might be explained by a failure to develop neutralizing antibodies 
because of simultaneous vaccination with other attenuated virus 
vaccines, which may have inhibited the replication of the other 
vaccinal virus due to the production of interferon27-29. Other factors 
that may influence the immune response to the vaccine against 
yellow fever include previous immunity against related antigens, 
crossed protection against flavivirus, immunosuppression due 
to diseases or drugs, severe undernutrition and pregnacy30, in 
addition to difficulties in the handling/preservation of the vaccine 
during administration. It has been shown that children aged 
12 months or less have reduced rates of serologic conversion and 
after vaccination against yellow fever when compared to children 
aged 2 years or more or to adults31.
Although the serologic test used in this study cannot 
distinguish between antibodies induced by natural infection 
from those induced by vaccination, the fact that 97.6% of the 
individuals tested showed protective antibody titers against 
yellow fever, in addition to the reducing incidence rates of the 
disease in the last decade, suggest that control actions including 
a wide vaccination programme have reached good results in 
the studied area.
It would be of additional interest to verify the immune 
response after (re)vaccination of the 9 volunteers who did not 
show immune protection, so that the absence or low immune 
response after vaccination could be confirmed, particularly in 
individuals who stated receiving prior vaccination.
This study reinforces the importance of surveys to address 
the immune state of a population at risk for yellow fever 
infection and to the surveillance of actions to control the disease 
in endemic areas.
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